Nykode Therapeutics (Norway) Performance
| NYKD Stock | 2.68 0.01 0.37% |
The company secures a Beta (Market Risk) of -0.29, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Nykode Therapeutics are expected to decrease at a much lower rate. During the bear market, Nykode Therapeutics is likely to outperform the market. At this point, Nykode Therapeutics ASA has a negative expected return of -0.89%. Please make sure to verify Nykode Therapeutics' total risk alpha, maximum drawdown, potential upside, as well as the relationship between the treynor ratio and value at risk , to decide if Nykode Therapeutics ASA performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Nykode Therapeutics ASA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's essential indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Nykode |
Nykode Therapeutics Relative Risk vs. Return Landscape
If you would invest 581.00 in Nykode Therapeutics ASA on September 3, 2024 and sell it today you would lose (313.00) from holding Nykode Therapeutics ASA or give up 53.87% of portfolio value over 90 days. Nykode Therapeutics ASA is generating negative expected returns and assumes 6.8705% volatility on return distribution over the 90 days horizon. Simply put, 61% of stocks are less volatile than Nykode, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Nykode Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nykode Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nykode Therapeutics ASA, and traders can use it to determine the average amount a Nykode Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1292
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NYKD |
Estimated Market Risk
| 6.87 actual daily | 61 61% of assets are less volatile |
Expected Return
| -0.89 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Nykode Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nykode Therapeutics by adding Nykode Therapeutics to a well-diversified portfolio.
Things to note about Nykode Therapeutics ASA performance evaluation
Checking the ongoing alerts about Nykode Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nykode Therapeutics ASA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nykode Therapeutics generated a negative expected return over the last 90 days | |
| Nykode Therapeutics has high historical volatility and very poor performance |
- Analyzing Nykode Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nykode Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Nykode Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nykode Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nykode Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nykode Therapeutics' stock. These opinions can provide insight into Nykode Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.